Hugo De Vuyst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4957357/publications.pdf

Version: 2024-02-01

567281 1,010 20 15 citations h-index papers

g-index 20 20 20 1294 docs citations times ranked citing authors all docs

752698

20

#	Article	IF	CITATIONS
1	Ageâ€specific burden of cervical cancer associated with <scp>HIV</scp> : A global analysis with a focus on <scp>subâ€Saharan</scp> Africa. International Journal of Cancer, 2022, 150, 761-772.	5.1	19
2	The impact of scaling up cervical cancer screening and treatment services among women living with HIV in Kenya: a modelling study. BMJ Global Health, 2020, 5, e001886.	4.7	10
3	Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2261-2268.	2.5	3
4	Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Global Health, 2019, 4, e001351.	4.7	158
5	Increased Cervical Human Immunodeficiency Virus (HIV) RNA Shedding Among HIV-Infected Women Randomized to Loop Electrosurgical Excision Procedure Compared to Cryotherapy for Cervical Intraepithelial Neoplasia 2/3. Clinical Infectious Diseases, 2018, 66, 1778-1784.	5.8	8
6	A Smartphone-Based Approach for Triage of Human Papillomavirus-Positive Sub-Saharan African Women: A Prospective Study. JMIR MHealth and UHealth, 2017, 5, e72.	3.7	16
7	Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 332-339.	2.1	77
8	Methylation Levels of CADM1, MAL, and MIR124-2 in Cervical Scrapes for Triage of HIV-Infected, High-Risk HPV-Positive Women in Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 311-318.	2.1	33
9	Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology, 2014, 448, 356-362.	2.4	29
10	Residual Disease and HPV Persistence after Cryotherapy for Cervical Intraepithelial Neoplasia Grade 2/3 in HIV-Positive Women in Kenya. PLoS ONE, 2014, 9, e111037.	2.5	20
11	The Burden of Human Papillomavirus Infections and Related Diseases in Sub-Saharan Africa. Vaccine, 2013, 31, F32-F46.	3.8	178
12	Recommendations for Cervical Cancer Prevention in Sub-Saharan Africa. Vaccine, 2013, 31, F73-F74.	3.8	29
13	Clustering patterns of human papillomavirus infections among HIV-positive women in Kenya. Infectious Agents and Cancer, 2013, 8, 50.	2.6	6
14	Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya. International Journal of Cancer, 2013, 133, 1441-1446.	5.1	17
15	Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. International Journal of Cancer, 2012, 131, 949-955.	5.1	62
16	The prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes and Control, 2010, 21, 2309-2313.	1.8	24
17	Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. International Journal of Cancer, 2008, 122, 244-246.	5.1	53
18	HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. European Journal of Cancer Prevention, 2008, 17, 545-554.	1.3	174

#	Article	lF	CITATIONS
19	Human papillomavirus vaccines in HIV-positive men and women. Current Opinion in Oncology, 2007, 19, 470-475.	2.4	16
20	Distribution of Human Papillomavirus in a Family Planning Population in Nairobi, Kenya. Sexually Transmitted Diseases, 2003, 30, 137-142.	1.7	78